BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9

• Press Releases

  Innovent’s Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

  January 9, 2026

   · 

  8 min read
• Press Releases

  Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

  January 9, 2026

   · 

  5 min read
• Press Releases

  MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

  January 9, 2026

   · 

  3 min read
• Press Releases

  Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

  January 9, 2026

   · 

  6 min read
• Press Releases

  O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated

  January 9, 2026

   · 

  4 min read
• Press Releases

  Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

  January 9, 2026

   · 

  2 min read
• Press Releases

  MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche

  January 9, 2026

   · 

  3 min read
• Press Releases

  CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

  January 9, 2026

   · 

  1 min read
• Press Releases

  Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

  January 9, 2026

   · 

  13 min read
• Press Releases

  MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

  January 9, 2026

   · 

  3 min read